Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials

European Heart Journal: Acute Cardiovascular Care

Volumn 5, Issue 3, 2016, Pages 253-262

  Capodanno, Davide ^a,b   Gargiulo, Giuseppe ^a   Capranzano, Piera ^a   Mehran, Roxana ^c   Tamburino, Corrado ^a,b   Stone, Gregg W ^c  

^a Ferrarotto Hospital   (Italy)

^b Excellence Through Newest Advances ETNA Foundation   (Italy)

^c New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; BIVALIRUDIN; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ARTICLE; BLEEDING; BRAIN ASYMMETRY; DRUG EFFICACY; EVALUATION AND FOLLOW UP; GENETIC HETEROGENEITY; HUMAN; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SYSTEMATIC REVIEW; AGED; COMPARATIVE STUDY; FEMALE; HEMORRHAGE; MALE; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST ELEVATION MYOCARDIAL INFARCTION;

AGED; FEMALE; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; ST ELEVATION MYOCARDIAL INFARCTION;

EID: 85016097910     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872615572599     Document Type: Article

References (21)

1. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
2. O'Gara PT, Kushner FG, Ascheim DD, et al. CF/AHA Task Force. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: 529-55.
3. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230.
4. Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377: 2193-2204.
5. Steg PG, van 't Hof A, Clemmensen P, et al. Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percutaneous coronary intervention. Am Heart J 2013;166: 960-967, e6.
6. Steg PG, van 't Hof A, Hamm CW, et al.; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369: 2207-2217.
7. Zeymer U, van 't Hof A, Adgey J, et al. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. Eur Heart J 2014; 35(36): 2460-2467.
8. Stone GW, Mehran R and Goldstein P. Bivalirudin vs. Heparin with or without Glycoprotein IIb/IIIa Inhibitors in Patients with STEMI Undergoing Primary PCI: Pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. J Am Coll Cardiol 2015; 65(1): 27-38.
9. Han Y; BRIGHT Investigators. Bivalirudin versus heparin plus tirofiban in patients with AMI undergoing PCI. http:// www.tctmd.com/show.aspx?id=126013. (2014, accessed 22 September 2014).
10. Schulz S, Richardt G, Laugwitz KL, et al.; Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Investigators; Bavarian Reperfusion Alternatives Evaluation BRAVE 4 Investigators. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur Heart J 2014; 35: 2285-2294.
11. Shahzad A, Kemp I, Mars C, et al.; for the HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014; S0140-6736(14)60924-7.
12. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2014; 35(37): 2541-2619.
13. Cassese S, Byrne RA, Laugwitz KL, et al. Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. EuroIntervention 2014; pii: 20140729e.
14. Cavender MA and Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet 2014; 384(9943): 599-606.
15. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100.
16. Clemmensen P. Predictors associated with acute stent thrombosis after primary PCI: Insights from the Euromax trial. American College of Cardiology (ACC) i2 Annual Scientific Session, 29 March 2014, Washington, DC.
17. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601-1606.
18. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 5: 797-804.
19. Anderson PR, Gogo PB, Ahemd B, et al. Two hour bivalirudin infusion aftr PCI for ST elevation myocardial infarction. J Thromb Thrombolysis 2011; 31: 401-406.
20. Valgimigli M, Calabro P, Cortese B, et al. Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site andSystemic Implementation of AngioX (MATRIX) trial. J Cardiovasc Transl Res 2014; 7: 101-111.
21. Bellomo R, Warrillow SJ and Reade MC. Why we should be wary of single-center trials. Crit Care Med 2009; 37: 3114-3119.